Guggenheim Initiates Coverage On CytomX Therapeutics with Buy Rating, Announces $16 Price Target

Guggenheim initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Buy rating and a $16 price target.

Benzinga · 11/20/2019 11:34

Guggenheim initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Buy rating and a $16 price target.